Overview

The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum

Status:
Completed
Trial end date:
2019-05-10
Target enrollment:
Participant gender:
Summary
This is a single-center, prospective, open-label, controlled, randomized, cross-over study in 34 prevalent end-stage renal disease patients on chronic hemodialysis treatment with hyperphosphatemia.
Phase:
Phase 2
Details
Lead Sponsor:
Prim. Priv. Doz. Dr. Daniel Cejka
Collaborator:
Vifor Fresenius Medical Care Renal Pharma
Treatments:
Ferric Compounds